Preview

Научно-практическая ревматология

Расширенный поиск

Индуцированный инфликсимабом волчаночно-подобный синдром у больной ревматоидным артритом (описание случая): случайность или закономерность?

https://doi.org/10.14412/1995-4484-2017-446-448

Полный текст:

Аннотация

В статье описывается случай развития волчаночно-подобного синдрома, индуцированного инфликсимабом, у больной ревматоидным артритом, с обсуждением возможных причин возникновения такой патологии.

Об авторах

Ю. В. Муравьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522 Москва, Каширское шоссе, 34А



В. В. Лебедева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522 Москва, Каширское шоссе, 34А


С. Ю. Аламанкина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522 Москва, Каширское шоссе, 34А


Список литературы

1. Wetter DA, Davis MDP. Lupus-like syndrome attributable to antitumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clinic Proc. 2009 Nov;84(11):979-84.doi: 10.1016/S0025-6196(11)60668-X

2. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-90. doi: 10.1016/j.berh.2006.06.002

3. Hoffman BJ. Sensitivity to sulfadiazine resembling acute disseminated lupus erythematosus. Arch Dermatol Syph. 1945;51:190-2. doi: 10.1001/archderm.1945.01510210032007

4. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82. doi: 10.1196/annals.1422.019

5. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15:757-61. doi: 10.1177/0961203306070000

6. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7. doi: 10.1002/art.1780251101

7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. doi: 10.1002/art.1780400928

8. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48:716-20. doi: 10.1093/rheumatology/kep080

9. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43:2383-90. doi: 10.1002/15290131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D

10. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus. 2002;11:753-5. doi: 10.1191/0961203302lu236cr

11. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008;37:381-7. doi: 10.1016/j.semarthrit.2007.08.003

12. Klapman JB, Ene-Stroscu D, Becker MA, Hanauer SB. A lupuslike syndrome associated with infiximab therapy. Inflamm Bowel Dis. 2003;9:176-8. doi: 10.1097/00054725-00305000-00005

13. Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximabinduced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-7. doi: 10.1016/S1590-8658(03)00448-1

14. Bleumink GS, ter Borg EJ, Ramselaar CG, Strickler BH. Etanercept-induced subacute cutaneous lupus erythemaotosus. Rheumatology. 2001;40:1317-9. doi: 10.1093/rheumatology/40.11.1317

15. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80. doi: 10.1016/S0140-6736(02)07714-0

16. Carlson E, Rothfield N. Etanercept-induced lupus like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum. 2003;48:1165-6. doi: 10.1002/art.11033

17. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis. 2002;61:1031-2. doi: 10.1136/ard.61.11.1031

18. Swale VJ, Perrett CM, Denton CP, et al. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol. 2003;28:604-7. doi: 10.1046/j.1365-2230.2003.01411.x

19. Kang M-J, Lee Y-H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci. 2006;21:946-9. doi: 10.3346/jkms.2006.21.5.946

20. Haake H, Kä neke J, Amann K, et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin. 2007;102:852-7. doi: 10.1007/s00063-007-1104-6

21. Van Rijthoven AWAM, Bijlsma JWJ, Canninga-Van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a preexisting anti-dsDNA antibody level. Rheumatology. 2006;45:1317- 9. doi: 10.1093/rheumatology/kel227

22. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA)in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65:889-94. doi: 10.1136/ard.2005.043166

23. De Bant M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti- tumor necrosis factor alpha therapy: a French survey. Arthritis Res Ther. 2005;7(3):R545-51. doi: 10.1186/ar1715

24. Ramos-Casal M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF- targeted therapies. Analysis of 233 cases. Medicine. 2007;86:242-51. doi: 10.1097/MD.0b013e3181441a68

25. Thornhill J, Watson KD, Lord PA, et al. Drug-induced lupus in patients with inflammatory arthritis treated with TNF blocking agents: results from the BSR Biologics Register. BSR Abstracts. 2008.

26. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in urine autoimmune 'lupus' nephritis. Nature. 1988;331:356-8. doi: 10.1038/331356a0

27. Kontoyiannis D, Kollias G. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumour necrosis factor. Eur J Immunol. 2000;30:2038-47. doi: 10.1002/1521-4141(200007)30:7<2038::AIDIMMU2038>3.0.CO;2-K

28. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumour necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989;52:421- 34. doi: 10.1016/0090-1229(89)90157-8

29. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res. 1999;20:147-61. doi: 10.1007/BF02786470

30. Romagnani S. Th1/Th2 cells. Inflamm Bowel Dis. 1999;5:285-94. doi: 10.1097/00054725-199911000-00009

31. Bickerstaff MC, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nat Med. 1999;5:694-7. doi: 10.1038/9544

32. Lorenz HM, Herrmann M, Winkler T, et al. Role of apoptosis in autoimmunity. Apoptosis. 2000;5:443-9. doi: 10.1023/A:1009692902805

33. Erikkson C, Engstrand S, Sundqvist K-G, Rantapaat-Dahlqvist S. Autoantibody formationin patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005;64:403-7. doi: 10.1136/ard.2004.024182

34. Zheng L, Fisher G, Miller R, et al. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 1995;377:348-51. doi: 10.1038/377348a0

35. Sarzi-Puttini P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoimmunity. 2005;38:507-18. doi: 10.1080/08916930500285857

36. D'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-α antibodies. J Intern Med. 2004;255:409-18. doi: 10.1111/j.1365-2796.2003.01298.x

37. Benucci M, Saviola G, Baiardi P, et al. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNF blocking agents in rheumatoid arthritis. Clin Rheumatol. 2008;27:91-5. doi: 10.1007/s10067-007-0728-5


Для цитирования:


Муравьев Ю.В., Лебедева В.В., Аламанкина С.Ю. Индуцированный инфликсимабом волчаночно-подобный синдром у больной ревматоидным артритом (описание случая): случайность или закономерность? Научно-практическая ревматология. 2017;55(4):446-448. https://doi.org/10.14412/1995-4484-2017-446-448

For citation:


Muravyev Yu.V., Lebedeva V.V., Alamankina S.Yu. INFLIXIMAB-INDUCED LUPUS-LIKE SYNDROME IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS (A CASE REPORT): AN ACCIDENT OR REGULARITY? Rheumatology Science and Practice. 2017;55(4):446-448. (In Russ.) https://doi.org/10.14412/1995-4484-2017-446-448

Просмотров: 369


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)